Armata Pharmaceuticals financials
$3.59−5.03%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $5.2M | $4.5M | $5.5M | $4.5M | $823.0K | — |
| Gross profit | $4.9M | $5.2M | $4.5M | $5.5M | $4.5M | $823.0K | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$36.6M | -$42.4M | -$40.9M | -$36.9M | -$23.8M | -$21.6M | -$19.1M |
| Net income | -$173.8M | -$18.9M | -$69.0M | -$36.9M | -$23.2M | -$22.2M | -$19.5M |
| Net margin | −3544.0% | −365.6% | −1524.5% | −670.2% | −517.5% | −2695.1% | — |
| Diluted EPS | $-4.80 | $-0.89 | $-1.91 | $-1.08 | $-0.96 | $-1.35 | $-2.55 |
| EBITDA | -$29.7M | -$41.1M | -$39.9M | -$36.1M | -$22.7M | -$20.5M | -$17.7M |
| Operating cash flow | -$25.8M | -$37.6M | -$47.4M | -$32.5M | -$23.6M | -$18.3M | -$15.6M |
| Free cash flow | -$26.3M | -$39.4M | -$55.6M | -$34.7M | -$24.9M | -$19.1M | -$15.8M |
| Diluted shares | 36.2M | 59.1M | 36.1M | 34.3M | 24.1M | 16.4M | 8.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.7M | $9.3M | $13.5M | $14.9M | $10.3M | $9.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $256.9M | $94.4M | $82.3M | $0.00 | $0.00 | $722.0K |
| Total assets | $76.9M | $86.4M | $98.4M | $95.8M | $69.8M | $39.5M |
| Total liabilities | $295.5M | $134.5M | $130.4M | $59.8M | $44.4M | $20.7M |
| Shareholders' equity | -$218.6M | -$48.0M | -$32.1M | $36.1M | $25.4M | $18.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology